Effects of salmon calcitonin on the bone loss induced by ovariectomy
- 1 October 1990
- journal article
- clinical trial
- Published by Springer Nature in Calcified Tissue International
- Vol. 47 (4) , 209-214
- https://doi.org/10.1007/bf02555921
Abstract
We present the results of a 12-month clinical study assessing the effects of synthetic salmon calcitonin (sCT) on a group of fertile white women who had undergone ovariectomy for uterine fibromatosis. The study was performed to verify whether CT can prevent the loss of bone mass and the changes in calcium-phosphorus metabolism associated with acute estrogen deficiency. The study consisted of an initial double-blind phase of 6 months, followed by a 6-month open period. Treated patients were given 100 MRC U of synthetic salmon CT injected i.m. in the morning, every other day, starting on the 7th day after the operation and continued for 12 months. Control patients received a placebo injection for the first 6 months; subsequently, they too were treated with sCT i.m. every other day for 6 months at the same dose as the 12 month-treated group. All patients received 500 mg of elementary calcium p.o., b.i.d. Bone mineral content (BMC) was measured at the extreme distal radius of the nondominant arm by a dual photon bone densitometer which utilizes two radio nuclides, 241 Am and 125 I, with energies of about 60 and 30 KeV. Biochemical parameters of the calcium-phosphorus metabolism were also measured. After 12 months of study, no significant changes of BMC were observed in the 12 months sCT treated group, while control patients, treated 6 months after the ovariectomy, showed a significant decrease in BMC values. Total hydroxyproline/ creatinine (OHPr/Cr) ratio, which increased after ovariectomy, returned to normal after the first month of sCT administration in the continuously treated group whereas it remained high in the control group up to the 6th month of observation, declining thereafter in coincidence with sCT treatment. The behavior of Bone GLA-protein (BGP), like that of the nondializable OHPr/Cr ratio, was substantially similar in both treated and control groups for the entire period of observation. These results show that prophylactic administration of salmon CT in ovariectomized women prevent estrogen deficiency-induced bone loss, inhibiting skeletal resorption and allowing osteogenesis to occur normally.Keywords
This publication has 36 references indexed in Scilit:
- CALCITONIN FOR PREVENTION OF POSTMENOPAUSAL BONE LOSSThe Lancet, 1988
- Relative Contributions of Aging and Estrogen Deficiency to Postmenopausal Bone LossNew England Journal of Medicine, 1984
- Bone density in women: A modified procedure for measurement of distal radial densityJournal of Orthopaedic Research, 1984
- Calcium malabsorption in the elderly: the effect of treatment with oral 25‐hydroxyvitamin D3European Journal of Clinical Investigation, 1983
- CALCITONIN AND THE CALCIUM-REGULATING HORMONES IN POSTMENOPAUSAL WOMEN: EFFECT OF OESTROGENSThe Lancet, 1981
- BONE MASS IN POSTMENOPAUSAL WOMEN AFTER WITHDRAWAL OF OESTROGEN/GESTAGEN REPLACEMENT THERAPYThe Lancet, 1981
- Estimation of Total Body Calcium from the Bone Mineral Content of the ForearmScandinavian Journal of Clinical and Laboratory Investigation, 1975
- EFFECTS OF ARTIFICIAL MENOPAUSE ON PLASMA AND URINE CALCIUM AND PHOSPHATEClinical Endocrinology, 1972
- Urinary polypeptides related to collagen synthesisJournal of Clinical Investigation, 1970
- A unified concept of osteoporosisThe American Journal of Medicine, 1965